Filing Details

Accession Number:
0001179110-21-009816
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-03 16:02:35
Reporting Period:
2021-11-01
Accepted Time:
2021-11-03 16:02:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
744218 Celldex Therapeutics Inc. CLDX In Vitro & In Vivo Diagnostic Substances (2835) 133191702
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1681854 Elizabeth Crowley C/O Celldex Therapeutics, Inc.
53 Frontage Road, Suite 220
Hampton NJ 08827
Sr. Vp &Cpdo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-01 8,555 $2.78 9,043 No 4 M Direct
Common Stock Disposition 2021-11-01 2,528 $44.12 6,515 No 4 S Direct
Common Stock Disposition 2021-11-01 600 $43.11 5,915 No 4 S Direct
Common Stock Disposition 2021-11-01 1,189 $41.62 4,726 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (Right to Buy) Disposition 2021-11-01 8,555 $0.00 8,555 $2.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,445 2029-06-19 No 4 M Direct
Footnotes
  1. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
  2. The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.710 to $44.420 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.580 to $43.360 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.400 to $41.990 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  6. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.